adenosine diphosphate ribose has been researched along with Carcinoma, Pancreatic Ductal in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, Y; Chen, L; Chen, Y; Cui, G; Deng, M; Deshpande, RA; Gao, H; Guo, G; Hou, J; Huang, J; Kim, W; Kloeber, JA; Liu, J; Lou, Z; Luo, K; Mer, G; Paull, TT; Shi, Y; Tao, K; Tu, X; Wu, Z; Xu, Z; Yan, Y; Yin, P; Yuan, J; Zeng, X; Zhang, C; Zhang, Y; Zhao, F; Zhou, Q; Zhu, Q; Zhu, S | 1 |
1 other study(ies) available for adenosine diphosphate ribose and Carcinoma, Pancreatic Ductal
| Article | Year |
|---|---|
METTL16 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in pancreatic ductal adenocarcinoma.
Topics: Adenosine Diphosphate Ribose; Carcinoma, Pancreatic Ductal; DNA; Exonucleases; Humans; Methyltransferases; MRE11 Homologue Protein; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; RNA; Synthetic Lethal Mutations | 2022 |